journal
MENU ▼
Read by QxMD icon Read
search

American Health & Drug Benefits

journal
https://www.readbyqxmd.com/read/27994714/factors-associated-with-adherence-to-the-hedis-quality-measure-in-medicaid-patients-with-schizophrenia
#1
Marie-Hélène Lafeuille, Christian Frois, Michel Cloutier, Mei Sheng Duh, Patrick Lefebvre, Jacqueline Pesa, Zoe Clancy, John Fastenau, Mike Durkin
BACKGROUND: Treatment continuity is a major challenge in the long-term management of patients with schizophrenia; poor patient adherence to antipsychotic drugs has been associated with negative clinical outcomes. Long-acting injectable therapies may improve adherence and lessen the risk for psychiatric-related relapse, often leading to rehospitalization and higher healthcare costs. Therefore, understanding the determinants of adherence to antipsychotics is critical in the management of patients with schizophrenia...
October 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27994713/evaluating-adherence-to-dilated-eye-examination-recommendations-among-patients-with-diabetes-combined-with-patient-and-provider-perspectives
#2
Maxine D Fisher, Yamina Rajput, Tao Gu, Joseph R Singer, Amanda R Marshall, Seonyoung Ryu, John Barron, Catherine MacLean
BACKGROUND: Diabetes mellitus remains the leading cause of new cases of blindness among US adults. Routine dilated eye examinations can facilitate early detection and intervention for diabetes-related eye disease, providing an opportunity to reduce the risk for diabetes-related blindness in working-aged Americans. The Healthcare Effectiveness Data and Information Set (HEDIS) established criteria for performing dilated eye examination in patients with diabetes. OBJECTIVES: To obtain information about adherence and nonadherence to diabetic eye examinations among insured patients to understand the barriers to routine dilated eye examinations, and to identify ways to improve the quality of care for these patients...
October 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27994712/examining-the-value-of-subsidies-of-health-plans-and-cost-sharing-for-prescription-drugs-in-the-health-insurance-marketplace
#3
Surachat Ngorsuraches, Jane R Mort
BACKGROUND: The Affordable Care Act (ACA) initiated federally and state-run health insurance exchanges, or marketplaces, with health plans offering subsidies for plan members as well as coverage for essential health benefits, to help individuals, families, and small businesses find health plans that fit their specific needs. A recent study found that the value of these healthcare subsidies varied with the number of health plans in the different geographic rating areas, but that study only examined the premiums and the deductibles of those health plans...
October 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924188/-learning-from-yellowstone-commencement-address-to-philadelphia-university-physician-assistants-graduating-class
#4
EDITORIAL
David B Nash
No abstract text is available yet for this article.
October 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924187/evaluating-outcomes-in-patients-with-overactive-bladder-within-an-integrated-healthcare-delivery-system-using-a-treatment-patterns-analyzer
#5
Daniel B Ng, Melissa McCart, Christopher Klein, Chelsey Campbell, Robert Schoenhaus, Todd Berner
BACKGROUND: Overactive bladder (OAB) is a relatively common disease that has been linked to a variety of comorbidities, reductions in quality of life, and increased healthcare costs. Antimuscarinic agents are the standard of care among pharmacologic treatments for OAB, but these drugs are linked to high levels of anticholinergic burden, especially in the elderly. OBJECTIVE: To demonstrate how efficient data analysis can be used to identify gaps in care as a result of improvement strategies for OAB within an integrated healthcare delivery system setting...
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924186/treatment-of-chronic-hepatitis-c-infection-with-sofosbuvir-based-regimens-in-a-commercially-insured-patient-population
#6
John Barron, Yiqiong Xie, Sze-Jung Wu, Jeff White, Joseph Singer, Bernard Tulsi, Alan Rosenberg
BACKGROUND: The response to treatment with direct-acting antiviral agents in patients with chronic hepatitis C virus (HCV) is not well-characterized in the real-world setting. OBJECTIVE: To describe patients' response to 3 sofosbuvir-based treatment regimens among commercially insured patients with chronic HCV. METHODS: In this observational study, we identified patients with HCV who started sofosbuvir treatment with 1 of 3 sofosbuvir-based regimens between December 1, 2013, and April 30, 2014, in the HealthCore Integrated Research Database, a large managed care repository...
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924185/employer-perspectives-on-a-specialty-drug-step-therapy-program-evaluation
#7
Matthew Harman, F Randy Vogenberg
No abstract text is available yet for this article.
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924184/revealed-opportunism-how-physicians-game-prior-authorization-protocols-until-they-are-rescinded
#8
Natan R Kahan, Dan-Andrei Waitman, David P Chinitz
BACKGROUND: Prior authorization (PA) is a management technique that has been implemented to manage the utilization of expensive drugs and to improve the precision of drug prescribing. PA requirements may incentivize physicians to document adverse effects, sometimes falsely, to meet the eligibility requirements. OBJECTIVES: To identify documentation patterns that may facilitate the quantitative analysis of physician gaming and underreporting behaviors associated with the prescribing of angiotensin-converting enzyme (ACE) inhibitors in a primary care setting, and to evaluate the effect of a PA requirement on the documentation of adverse events as a way to receive approval for more expensive drugs...
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924183/eye-of-the-consolidation-storm
#9
EDITORIAL
David B Nash
No abstract text is available yet for this article.
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625745/oncologist-support-for-consolidated-payments-for-cancer-care-management-in-the-united-states
#10
Siva Narayanan, Emily Hautamaki
BACKGROUND: The cost of cancer care in the United States continues to rise, with pressure on oncologists to provide high-quality, cost-effective care while maintaining the financial stability of their practice. Existing payment models do not typically reward care coordination or quality of care. In May 2014, the American Society of Clinical Oncology (ASCO) released a payment reform proposal (revised in May 2015) that includes a new payment structure for quality-of-care performance metrics...
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625744/hospital-and-health-plan-partnerships-the-affordable-care-act-s-impact-on-promoting-health-and-wellness
#11
Michelle Vu, Annesha White, Virginia P Kelley, Jennifer Kuca Hopper, Cathy Liu
BACKGROUND: The Affordable Care Act (ACA) healthcare reforms, centered on achieving the Centers for Medicare & Medicaid Services (CMS) Triple Aim goals of improving patient care quality and satisfaction, improving population health, and reducing costs, have led to increasing partnerships between hospitals and insurance companies and the implementation of employee wellness programs. Hospitals and insurance companies have opted to partner to distribute the risk and resources and increase coordination of care...
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625743/impact-of-pharmacist-provided-medication-therapy-management-on-healthcare-quality-and-utilization-in-recently-discharged-elderly-patients
#12
Jordan D Haag, Amanda Z Davis, Robert W Hoel, Jeffrey J Armon, Laura J Odell, Ross A Dierkhising, Paul Y Takahashi
BACKGROUND: The optimization of medication use during care transitions represents an opportunity to improve overall health-related outcomes. The utilization of clinical pharmacists during care transitions has demonstrated benefit, although the optimal method of integration during the care transition process remains unclear. OBJECTIVE: To evaluate the impact of pharmacist-provided telephonic medication therapy management (MTM) on care quality in a care transitions program (CTP) for high-risk older adults...
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625742/improving-population-health-by-working-with-communities
#13
EDITORIAL
David B Nash
No abstract text is available yet for this article.
July 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688835/innovation-tops-current-trends-in-the-2016-oncology-drug-pipeline
#14
Dalia Buffery
No abstract text is available yet for this article.
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688834/thromboembolic-events-associated-with-bevacizumab-plus-chemotherapy-for-patients-with-colorectal-cancer-a-meta-analysis-of-randomized-controlled-trials
#15
Abdullah K Alahmari, Ziyad S Almalki, Ahmed K Alahmari, Jeff J Guo
BACKGROUND: Bevacizumab is a recombinant, humanized monoclonal antibody that hinders the proliferation of new blood vessels required for malignant progression. The drug is considered safe and tolerable; however, some controversy remains about whether it is linked to venous and arterial thromboembolic events (TEEs). OBJECTIVE: To evaluate the risk for overall, venous, and arterial TEEs in patients with colorectal cancer (CRC) who are administered bevacizumab plus chemotherapy in randomized controlled trials (RCTs)...
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688833/economic-burden-of-toxicities-associated-with-treating-metastatic-melanoma-in-the-united-states
#16
S Pinar Bilir, Qiufei Ma, Zhongyun Zhao, Elizabeth Wehler, Julie Munakata, Beth Barber
BACKGROUND: Little has been reported on the costs of managing the adverse events (AEs) associated with current therapies for patients with regional or distant metastatic melanoma. OBJECTIVES: To identify treatment-related AEs in patients with metastatic melanoma and to estimate the associated costs of treating these AEs in the United States. METHODS: A cost-estimation study for AEs associated with treatment of metastatic melanoma was conducted from 2012 to 2013 by identifying grades 3 and 4 AEs through the use of a comprehensive search of drug labels and English-language, published phase 2/3 studies in PubMed, conference abstracts, and the National Comprehensive Cancer Network guidelines...
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27688832/patient-reported-outcomes-in-oncology-drug-labeling-in-the-united-states-a-framework-for-navigating-early-challenges
#17
Alan L Shields, Yanni Hao, Meaghan Krohe, Andrew Yaworsky, Iyar Mazar, Catherine Foley, Faisal Mehmed, Denise Globe
BACKGROUND: Despite an increased use of patient-reported outcomes (PROs) in oncology clinical trials, integrating the patient perspective into drug approval decisions and documentation has been challenging. OBJECTIVES: To review important regulatory and measurement terminology, and to provide oncology outcomes researchers and those involved with building oncology programs with tools to plan PRO data collection, particularly in relation to drug efficacy claims for drug labeling in the United States...
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625741/navigating-the-hassle-map
#18
EDITORIAL
David B Nash
No abstract text is available yet for this article.
June 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625740/implications-of-real-world-data-and-pharmacoeconomics-for-managed-care
#19
Lilly Ostrovsky
The following summaries represent a sample of the many real-world, evidence-based studies presented at the 28th Annual Meeting of the Academy of Managed Care Pharmacy (AMCP), April 19-22, 2016, in San Francisco, CA. These studies highlight some of the main trends in the current US healthcare with important implications for payers, employers, drug manufacturers, providers, patients, and other healthcare stakeholders.
May 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27625739/in-silico-pharmacology
#20
EDITORIAL
David B Nash
No abstract text is available yet for this article.
May 2016: American Health & Drug Benefits
journal
journal
48448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"